Ketamine for the treatment of prehospital acute pain: a systematic review of benefit and harm by Sandberg, Mårten et al.
1Sandberg M, et al. BMJ Open 2020;10:e038134. doi:10.1136/bmjopen-2020-038134
Open access 
Ketamine for the treatment of 
prehospital acute pain: a systematic 
review of benefit and harm
Mårten Sandberg,1,2 Per Kristian Hyldmo,3,4,5 Poul Kongstad,6 
Kristian Dahl Friesgaard,7,8 Lasse Raatiniemi   ,9,10 Robert Larsen,11,12 
Vidar Magnusson,13 Leif Rognås   ,14,15,16 Jouni Kurola,17,18 Marius Rehn   ,1,3,4 
Gunn Elisabeth Vist19
To cite: Sandberg M, 
Hyldmo PK, Kongstad P, et al.  
Ketamine for the treatment 
of prehospital acute pain: 
a systematic review of 
benefit and harm. BMJ Open 
2020;10:e038134. doi:10.1136/
bmjopen-2020-038134
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 038134).
Received 28 February 2020
Revised 19 September 2020
Accepted 30 October 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Marius Rehn;  
 rehmar@ snla. no
Original research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background Few publications have addressed 
prehospital use of ketamine in analgesic doses. We 
aimed to assess the effect and safety profile of ketamine 
compared with other analgesic drugs (or no drug) in adult 
prehospital patients with acute pain.
Methods A systematic review of clinical trials assessing 
prehospital administration of ketamine in analgesic doses 
compared with other analgesic drugs or no analgesic 
treatment in adults. We searched PubMed, EMBASE, 
Cochrane Library and Epistemonikos from inception 
until 15 February 2020, including relevant articles in 
English and Nordic languages. We used the Cochrane and 
Grading of Recommendations Assessment, Development 
and Evaluation methodologies and exclusively assessed 
patient- centred outcomes. Two independent authors 
screened trials for eligibility, extracted data and assessed 
risk of bias.
Results We included eight studies (2760 patients). 
Ketamine was compared with various opioids given alone, 
and intranasal ketamine given with nitrous oxide was 
compared with nitrous oxide given alone. Four randomised 
controlled trials (RCTs) and one cluster randomised trial 
included 699 patients. One prospective cohort included 
27 patients and two retrospective cohorts included 2034 
patients. Five of the eight studies had high risks of bias. 
Pain score with ketamine is probably lower than after 
opioids as demonstrated in a cluster- RCT (308 patients) 
and a retrospective cohort (158 patients) study, Δvisual 
analogue scale −0.4 (−0.8 to 0.0) and Δnumeric pain 
rating scale −3.0 (−3.86 to −2.14), respectively. Ketamine 
probably leads to less nausea and vomiting (risk ratio (RR) 
0.24 (0.11 to 0.52)) but more agitation (RR 7.81 (1.85 to 
33)) than opioids.
Conclusions This systematic literature review finds that 
ketamine probably reduces pain more than opioids and 
with less nausea and vomiting but higher risk of agitation. 
Risk of bias in included studies is high.
Other Scandinavian society of anaesthesiology and 
intensive care medicine funded meetings and software. 
The Norwegian Air Ambulance Foundation funded 
publication. Otherwise this research received no grant 
from any agency in the public, commercial or not- for- profit 
sectors.
PROSPERO registration number CRD42018114399.
INTRODUCTION
Prehospital acute pain is a frequent symptom 
and often inadequately managed.1–3 Several 
analgesics are administered by prehospital 
emergency medical services throughout the 
world without solid evidence of their efficacy 
and safety. The heterogeneity in pain manage-
ment strategies may reflect the varying 
competence levels of providers ranging 
from technicians with basic training to 
specially trained physicians. Opioids are most 
frequently used, but their cerebral, haemo-
dynamic and respiratory side effects remain 
a potential challenge in unstable and undif-
ferentiated prehospital patients.4 Ketamine 
is an alternative to opioids. Ketamine exerts 
its effects mainly as an N- methyl- D- aspartate 
antagonist and, depending on the dose, can 
be considered as an analgesic, a sedative or 
an anaesthetic drug.5 One attractive feature 
for prehospital use of ketamine is its ability 
to preserve upper airway reflexes. Respiratory 
rate may increase, and ketamine can cause 
bronchodilation. While ketamine generally 
preserves respiratory function, ketamine can 
cause respiratory depression if given quickly.6 
There is a risk of laryngospasm, which may 
require intubation in a very small fraction of 
cases.7
Ketamine can be administered in a variety 
of routes, most commonly intramuscularly, 
Strengths and limitations of this study
 ► A systematic review where main outcomes 
were assessed according to the Grading of 
Recommendations Assessment, Development and 
Evaluation method.
 ► Studies were heterogeneous in terms of setting, pa-
tient population, outcomes and comparators.
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intranasally and intravenously, although per oral and 
per rectal doses are used in different settings. Although 
originally believed to cause an increase in intracranial 
pressure (ICP), recent work in critical care patients indi-
cates that ketamine has little or no impact on ICP. In two 
studies comparing ketamine and sufentanil, the authors 
concluded that ketamine did not affect ICP and that it 
was safe to administer to patients with traumatic brain 
injury (TBI).8 9 In another study, ketamine in conjunc-
tion with propofol was administered to patients with TBI, 
and a significant decrease in ICP was recorded.10 In one 
study on children with TBI, a reduction in ICP by up to 
30% was found, and cerebral perfusion was improved.11 
In these studies, ketamine was used in anaesthetic doses, 
and the results should be interpreted with caution.
Moderate or severe agitation occurs in 5%–30% of 
adult patients; some clinicians administer boluses of 
midazolam to avoid this phenomenon.6 A randomised 
controlled trial (RCT) showed that this practice signifi-
cantly reduced agitation in adults; however, one trial 
found that it did not reduce agitation in children.6 12
Proper pain relief allows prehospital care providers 
to meet essential clinical endpoints, for example, facili-
tating fracture manipulation. Although analgesia should 
be titrated for the desired effect, pain relief is frequently 
suboptimal, possibly due to concerns about adverse 
events.13 Ketamine may be a useful prehospital analgesic 
mainly due to its ability to provide excellent analgesic 
effects with a lower incidence of respiratory depression 
than that caused by opioids. These positive effects have 
been demonstrated in fracture management,14 burn 
treatment15 and traumatic amputation.16
The aim of this systematic literature review is to explore 
the benefit and harm of ketamine compared with other 
analgesic drugs (or no drug) in prehospital patients with 
acute pain.
METHODS
We conducted this systematic review according to the 
Cochrane Handbook for systematic reviews of interven-
tions17 and as described in our protocol as specified below.
Inclusion criteria
We used the following inclusion criteria:
Population
Adult patients (18 years of age or older) with acute pain 




Other analgesics, no analgesics or ketamine given in 
another dose or another route of administration or 
ketamine given in combination with other analgesics
Outcomes
Pain reduction, speed of onset, duration of effect and rele-
vant adverse events such as mortality, morbidity, anaphy-
laxis, nausea and vomiting, hypotension, respiratory 
failure, loss of airway patency, emergence phenomena (as 
defined by study authors).
We included all adult patients (18 years of age or older) 
with acute pain, regardless of aetiology, managed in the 
prehospital setting. We also sought to identify adverse 
effects that are not previously reported. The following 
study designs were considered eligible for inclusion in 
the meta- analysis: RCTs, non- randomised controlled 
studies, cohort studies with a control group, interrupted 
time series and controlled before- and- after studies. Case 
series were also included for information relating to 
safety. Systematic reviews of high- quality answering to 
our inclusion criteria were evaluated for eligible studies. 
Other systematic reviews would have been used to check 
for relevant references.
Exclusion criteria
Children (younger than 18 years of age) and patients 
with chronic pain and/or patients who used ketamine as 
part of their regular treatments were not included in this 
review. We excluded all studies that were not conducted 
in the prehospital setting as well as conference abstracts, 
letters and publications without full texts available.
Search strategy
An experienced research librarian in collaboration with 
the authors developed the search strategy based on the 
inclusion criteria. The following databases were searched 
from their inception: PubMed, EMBASE, Cochrane 
Library and Epistemonikos.
The most recent search was conducted on 15 February 
2020, and the full search strategy is presented in online 
supplemental appendix 1. The search was limited to the 
following languages: Danish, English, Finnish, Icelandic, 
Norwegian and Swedish.
The reference lists of the included publications were 
checked in order to identify relevant articles not found in 
the original search.
Study selection
For each step in the review process, no assessor handled 
publications they had coauthored. MS and either PKH, 
MR or PK independently assessed all titles and abstracts 
identified from the search according to the inclusion 
criteria above. References that were considered poten-
tially relevant were collected, and the full- text articles 
were assessed independently by two assessors using the 
same inclusion criteria. Any disagreement between the 
initial two assessors was discussed and resolved by all asses-
sors. The process of study selection based on titles and 
abstracts, study selection based on full- text articles and 
risk of bias assessments were conducted using Covidence 
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Innovation, Melbourne, Australia. Available at www. covi-
dence. org).
Assessment of risk of bias
MS and either PKH, MR or PK independently assessed the 
risk of bias for each of the included studies in accordance 
with the recommendations by the Cochrane Collabora-
tion.17 For RCTs, the following items were assessed for risk 
of bias: (1) sequence generation, (2) concealment of allo-
cation, (3) blinding of participants and personnel, (4) 
blinding of outcome assessor, (5) incomplete outcome 
data, (6) selective outcome reporting and (7) other risk 
of bias. For non- RCTs and other studies with a control 
group, the following items were also assessed for risk of 
bias: (8) similarity of baseline characteristics, (9) simi-
larity of baseline outcome data and (10) contamination. 
All items were rated as either high, unclear or low risk of 
bias.
Data extraction
MS and either PKH or PK independently extracted data 
from each included study. We extracted data pertaining 
to full references; study design and country in which the 
study was conducted; characteristics of the population, 
for example, number of patients; age; gender; cause of 
pain; setting and context; type and dose of analgesics 
given; cadre/competency of the healthcare personnel 
who administered the analgesic; comparison/control 
intervention; attrition; outcomes and follow- up times. We 
did not contact any study investigators to obtain informa-
tion not described in the original articles.
The process of study selection based on titles and 
abstracts, study selection based on full- text articles as 
well as risk of bias assessments were conducted using 
Covidence.
Statistical analysis
Dichotomous outcomes are presented as risk ratios (RRs) 
with 95% CIs. Continuous outcomes are presented as the 
mean difference between the groups with 95% CIs. If 
different scales were used to measure the same outcome, 
we would have calculated standardised mean difference 
with a 95% CI. We used Review Manager (RevMan V.5.3) 
software to generate forest plots. Attrition was handled 
using intention- to- treat analysis. We evaluated statistical 
heterogeneity using the Q test and I2- statistic. Analysis was 
by inverse variance and random effects methods. Zero 
events were presented descriptively.
Grading our confidence in the evidence
We assessed our confidence in the evidence for each 
outcome using the Grading of Recommendations 
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Assessment, Development and Evaluation (GRADE) 
method.18 Our confidence is presented as high, moderate, 
low or very low. The evidence across each outcome is 
assessed by eight criteria. Five criteria lowered our confi-
dence in the evidence: (1) risk of bias/methodological 
limitations, (2) consistency between studies (statistical 
heterogeneity), (3) directness (similar study participants, 
intervention, comparator and outcome measures in the 
included studies to the population and target interven-
tions and measures), (4) precision of results and (5) 
reporting bias. Three criteria were used to consider 
upgrading evidence from observational studies that had 
not been downgraded: (1) strong or very strong associa-
tion between intervention and outcome,; (2) large or very 
large dose response and (3) situations where all plausible 
confounders would have reduced the effect. For ques-
tions about the effect of interventions, RCTs started at 
high confidence, and observational studies started at low 
confidence.
Breach of protocol
We did make a breach of protocol; the largest study 
(Losvik et al) we included also contained treatment data 
from a few children.19
Patient and public involvement
The development of the research question and outcome 
measures were informed by studies indicating that 
prehospital acute pain is a frequent symptom and often 
inadequately managed.1–3 No patients were directly 
involved in the design or conduct of this study.
The results will be disseminated as a part of a Scandina-
vian society of anaesthesiology and intensive care medi-
cine guideline on prehospital pain management.
RESULTS
The systematic literature search identified 1197 refer-
ences; we considered 60 to be potentially relevant and 
assessed those publications in full. We included seven of 
these studies in the final analysis. In addition, two unique 
references in the reference lists of the seven publications 
were assessed and one of the references was also included. 
Figure 1 shows the flow diagram of the identified refer-
ences. The 53 studies that were assessed in full- text arti-
cles and excluded are presented in online supplemental 
appendix 2 with the reason for their exclusion.
Characterisation of the trials
The eight included studies were conducted in Australia,20 
Canada,21 France,22 23 Iraq,19 Sweden,24 USA25 and 
Vietnam.26 A total of 2760 prehospital patients with acute 
pain were included in these eight studies. Four RCTs20–23 
and one cluster randomised trial26 included 699 patients. 
One prospective cohort study24 included 27 patients. Two 
retrospective cohort studies19 25 included 2034 patients. 
The largest of these studies, with 1876 patients, was 
conducted in the war zones and mine fields of northern 
and central Iraq.19 Two authors stated that their studies 
were conducted in rural areas, with one in Australia and 
one in Vietnam. The latter study included areas with mine 
fields, and three patients had been involved in mine acci-
dents. This study also included children; however, the vast 
majority of included patients was probably adults because 
the mean ages of the groups were 35.5 years and 36.9 
years. Therefore, this study was included. The reported 
time frame was similar in all studies; that is, from drug 
administration to admission to hospital.
Risk of bias assessment
Our assessments regarding each bias domain are provided 
in figure 2. Three of the five RCTs had a high risk of bias, 
with the main reasons being lack of random sequence 
generation, lack of allocation concealment or lack of 
blinding of patients, personnel and outcome assessors.
Comparisons
The included studies covered five comparisons involving 
ketamine (table 1):
 ► Ketamine intravenous versus opioids (morphine,26 
fentanyl,25 pentazocine19) intravenous.
 ► Ketamine intravenous and morphine intravenous 
versus only morphine intravenous.20 23 24
 ► Ketamine intravenous given as continuous adminis-
tration versus ketamine intravenous as single dose.22
 ► Ketamine intranasally and nitrous oxide versus only 
nitrous oxide.21
























































































































































 Randomised controlled trials 
Andolfatto 2019 + + + ? + + + + 
Galinski 2007 + + ? ? + + ? + 
Jennings 2012 ? + - - + + + + 
Tran 2014 - - - - + + + + 
Wiel 2015 + + + - + ? + + 
 Cohorts 
Bronsky 2019 NA NA + - + + + + 
Johansson 2009 NA NA - - + + + + 
Losvik 2015 NA NA + - + ? + - 
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Table 1 Summary of included studies
Reference
Study design
Country Ketamine Comparison Outcomes
Ketamine intravenous vs opioids intravenous
Bronsky et al 25 2019
Retrospective cohort
USA
n=79, ketamine 0.3 mg/kg 
intravenous every 20 min as 
needed, maximum three doses
n=79, fentanyl 2 µg/kg bolus 
intravenous over 1 to 2 min with 
additional dose every 10 min as 
needed
Change in pain scores, serious 
adverse events, GCS
Losvik et al 19 2015
Retrospective cohort
Iraq
n=713, ketamine 0.2 mg/kg 
intravenous, in case of unrest, 
5 mg diazepam intravenous. 
During protracted evacuations 
with repeated ketamine doses, 
1 mg atropine was administered. 
Repeat doses of ketamine 
allowed.
n=888, pentazocine 0.4 mg/kg 
intravenous for adults, repeat 
doses allowed
Change in physiological severity 
score
Tran et al26 2014
Cluster—RCT
Vietnam
n=169, ketamine 0.2 to 0.3 mg/
kg was administered as slow 
intermittent intravenous injections
n=139, morphine administered 
in one single i.m. dose; 10 mg for 
adult patients, 5 mg for paediatric 
patients
Change in pain score, serious 
adverse events, adverse events, 
satisfaction, mean treatment time 
(head trauma)
Ketamine and morphine intravenous vs morphine intravenous alone
Galinski et al 23 2007
RCT
France
n=33, ketamine 0.2 mg/kg 
intravenous in 3 mg morphine 
every 5 min if necessary
n=32, morphine 3 mg intravenous 
every 5 min if necessary
Change in pain score, adverse 
events
Jennings et al20 2012
RCT
Australia
n=70, morphine 5 mg intravenous 
initial dose followed by a 
ketamine bolus of 10 or 20 mg 
according to body size, followed 
by 10 mg ketamine every 3 min 
thereafter until pain was relieved
n=65, morphine 5 mg intravenous 
initial dose followed by 5 mg 
intravenous every 5 min until pain 
was relieved
Change in pain score, adverse 
events, GCS
Johansson et al 24 2009
Prospective cohort
Sweden
n=16, morphine 0.1 mg/kg 
intravenous followed by ketamine 
0.2 mg/kg if pain score ≥4 after 
5 min
n=11, mg/kg morphine 0.1 mg/kg 
intravenous followed by morphine 
0.1 mg/kg if pain score ≥4 after 
5 min
Change in pain score, adverse 
event, mean treatment time
Ketamine continuous intravenous administration vs ketamine intravenous one dose
Wiel et al 22 2015
RCT
France
n=30, all patients received 
ketamine 0.2 mg/kg intravenous 
bolus combined with morphine 
0.1 mg/kg intravenous followed by 
ketamine 0.2 mg/kg/h. Additional 
morphine 0.05 mg/kg was allowed 
every 5 min if VAS>3/10
n=33, all patients received a 
ketamine 0.2 mg/kg intravenous 
bolus combined with morphine 
0.1 mg/kg intravenous followed 
by a saline infusion of the same 
volume. Additional morphine 
0.05 mg/kg was allowed every 
5 min if the VAS>3/10
Change in pain score, adverse 
events, satisfaction




n=60, all patients received 
approximately 0.75 mg/kg 
intranasal ketamine (30 mg 
for patients<50 kg, 50 mg for 
patients 50–100 kg, 75 mg for 
patients>100 kg) combined with 
inhaled nitrous oxide
n=60, all patients received inhaled 
nitrous oxide
Change in pain score, adverse 
events, satisfaction
Ketamine intravenous vs no analgesic treatment
Losvik et al 19 2015
Retrospective cohort
Iraq
n=713, ketamine 0.2 mg/kg 
intravenous, in case of unrest, 
5 mg diazepam intravenous. 
During protracted evacuations 
with repeated ketamine doses, 
1 mg atropine was administered. 
Repeat doses of ketamine 
allowed.
n=275, no analgesic treatment Change in physiological severity 
score
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 ► Ketamine intravenous versus no analgesia/no 
medication19
In table 1, we give a short description of the included 
studies and the doses used, while the excluded studies are 
presented with the reason for their exclusion in online 
supplemental appendix 2. One study contributed to two 
comparisons,19 meaning that 713 patients who received 
ketamine are compared two times, first with patients who 
received opioids and again with patients who did not 
receive analgesic treatment.
Ketamine versus opioids
A change in pain score was reported in two studies. 
Bronsky et al25 used the numeric pain rating scale (NRS), 
where 1 represents no pain and 10 represents extreme 
pain, while Tran et al26 measured the change in pain using 
the visual analogue scale (VAS) but did not explicitly 
give a range. Figure 3 shows that both studies reported a 
greater reduction in pain scores with ketamine than with 
the opioids fentanyl (Mean Difference (MD) −3.0 (95% 
CI −3.86 to 2.14)) and morphine (MD −0.4 (95% CI −0.08 
to 0.0)).
The main outcome in the study by Losvik et al19 was the 
physiological severity score (PSS). The PSS was calculated 
from the blood pressure, respiratory rate and conscious-
ness level.27 They reported exactly the same change, at 1.5 
(95% CI 1.4 to 1.6), in the PSS for both the ketamine and 
the pentazocine groups. Hence, no difference was found 
between the treatment groups.
Adverse events were reported in the Vietnamese study26; 
fewer patients with nausea and vomiting were found in 
the ketamine group than in the morphine group and 
fewer patients with agitation were found in the morphine 
group than in the ketamine group (figure 4).
In the study where ketamine and fentanyl were 
compared,25 four adverse events were reported: two 
patients experienced respiratory compromise and two 
patients suffered haemodynamic instability. All four 
patients were in the fentanyl group.
The change in Glasgow coma scale (GCS) was measured 
by Bronsky et al25 and found to be similar for ketamine 
and fentanyl, MD −0.13 (95% CI −0.33 to 0.07).
Ketamine and morphine versus only morphine
Changes in the pain scores were measured in both the 
Australian20 and in the Swedish study24 using a scale 
from 1 to 10 where 10 represented extreme pain. In the 
French study,23 a scale from 0 to 100 was used, and we 
have transferred this to a 0 to 10 scale in order to include 
this study in the meta- analysis. Figure 5 shows the change 
in the pain score when prehospital patients received both 
ketamine and morphine compared with patients who 
received only morphine. Although the RCT performed 
by Jennings et al20 found lower pain scores in patients 
receiving combined ketamine and morphine than in 
patients receiving only morphine. When combined with 
the RCT by Galinski et al,23 the meta- analysis shows a non- 
significant reduction (MD −1.51 (95% CI −3.36 to 0.33)) 
in pain score. The small prospective cohort28 also found 
a non- significant reduction (MD −1.30 (95% CI −2.95 to 
0.35)) in pain score.
Adverse events were measured in both studies, and the 
results are illustrated in figure 6. It is important to note 
that the nausea and vomiting are included in the total 
adverse events in the RCTs. These results are character-
ised by few events but indicate that morphine alone may 
lead to fewer adverse events than the combination of 
ketamine and morphine.
Figure 3 Ketamine versus opioids—change in pain score.
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The RCT by Jennings et al20 measured the GCS score 
and found that the median score was unchanged between 
initial assessment and the follow- up time, with a median 
score of 15 for both groups.
The French RCT reported use of fewer boluses of 
morphine when combined with ketamine (1 bolus (95% 
CI 0 to 2) compared with 2.3 boluses (95% CI 1.8 to 3.8) 
when using morphine alone).22
The Swedish, prospective cohort by Johansson et al28 
reported a non- significant trend for shorter treatment 
time with morphine alone than with ketamine and 
morphine combined (10 min (95% CI −1.4 to 21.4)). 
Ketamine was administered nasally, thereby avoiding the 
need for intravenous access.
Continuous ketamine administration versus ketamine given as a 
bolus
One multicentre RCT conducted in France compared the 
continuous administration of ketamine with a bolus dose 
of ketamine but both groups also received morphine.22 
Changes in pain were measured using a VAS from 0 to 10 
(worst) and were similar in both groups (VAS −0.6 (95% 
CI −1.84 to 0.64)).
The main outcome of this study was the amount of addi-
tional morphine used (mg/kg) (p=0.18), indicating that 
there was no difference between the continuous group, at 
0.048 (first quartile, third quartile 0.000, 0.150), and the 
bolus group, at 0.107 (first quartile, third quartile 0.052, 
0.150). The duration of care for both groups was 35 min. 
Nausea and vomiting were not reported in patients in the 
continuous group but were reported in three patients in 
the bolus group.
Ketamine and nitrous oxide versus only nitrous oxide
Andolfatto et al used a verbal NRS pain score and evalu-
ated the scores after 15 min and 30 min21 More patients 
in the ketamine and nitrous oxide group had a reduction 
in pain of 2 or more points than those in the saline and 
nitrous oxide group at both time points (figure 7).
They reported no serious adverse effects in either 
group, but a considerable number of minor adverse 
events, such as feeling of unreality, dizziness, nausea, 
fatigue, general discomfort, mood change, hallucination, 
change in hearing and headache, occurred. Most of these 
side effects (52 of 66 events) were reported in the group 
of patients who received ketamine and nitrous oxide 
combined, as shown in figure 8.
Ketamine versus no analgesic treatment
The retrospectively matched observational study of 
patients/causalities in the war zone in Iraq compared the 
use of ketamine with no analgesic treatment.19 The main 
outcome in this study was the PSS, which was calculated 
from the blood pressure, respiratory rate and conscious-
ness level. There was a non- significant trend for lower PSS 
with ketamine compared with no analgesics (MD −0.2 
(95% CI −0.42 to 0.02)).
Figure 5 Combined ketamine and morphine compared with only morphine—change in pain score.
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Adverse events from ketamine across the five comparisons
Seven of the eight studies reported on adverse events 
and/or side effects from use of ketamine. Five studies 
reported on nausea and vomiting from ketamine alone 
(8/169),26 from ketamine continuous administration 
(0/30),22 from ketamine bolus administration (3/33)22 
and from combined ketamine and morphine (8/33),23 
(4/70),20 (7/16).24 Time for administering each bolus 
was not reported. Only one study reported on agitation, 
from ketamine alone (19/169).26 Four studies reported 
adverse events, and two stated that nausea and vomiting 
were included as adverse events, from ketamine and 
morphine (21/33),23 (27/70).20 One study reported 
adverse events from ketamine and nitrous oxide (52/60)21 
and one study reported no adverse events from ketamine 
alone (0/79).25
GRADE
The quality of the main outcomes for the comparisons 
involving the use of ketamine for the treatment of prehos-
pital acute pain was assessed according to the GRADE 
method.18 The quality of evidence could be down-
graded for various reasons (risk of bias, inconsistency, 
indirectness, imprecision and publication bias). Conse-
quently, the quality of the evidence was classified as high, 
moderate, low or very low. As described in table 2, we 
have for many of these outcomes downgraded for study 
limitations/high risk of bias or for imprecision because 
there were few events in many of these studies.
DISCUSSION
In this systematic review addressing the effect and safety 
of prehospital administration of ketamine in analgesic 
doses, we included eight studies with 2760 patients in 
total.
Strengths and limitations of this systematic review
The included studies were heterogeneous in terms of 
setting, patient population and outcomes explored as well 
as in their comparators, such as intravenous or intranasal 
ketamine with a variety of opioids or with nitrous oxide. 
In addition, a single dose of ketamine was compared with 
ketamine that was administered continuously.
Although the evidence base includes five RCTs, five of 
the eight included studies have a high risk of bias. The 
RCTs were relatively small studies with 63, 65, 120, 135 
and 308 patients included, respectively. None of the 
studies was designed or powered to truly test the safety 
of ketamine. Adverse events and the severity thereof were 
inconsistently reported.
The eight studies cover five different comparisons, 
so the amount of research evidence for each compar-
ison is sparse. Only one of the outcomes in one of the 
comparisons has been measured in more than one study 
of similar design, and several of the outcomes have not 
been assessed in a prehospital study at all. When using 
GRADE to assess our confidence in the estimates, we 
more often than not, downgraded for high risk of bias 
or imprecision due to very few events or wide CIs. Three 
of the eight included studies are observational studies. 
They have an initial high risk of bias compared with 
RCTs due to the lack of randomisation. This is acknowl-
edged in GRADE where observational studies start at low 
quality of evidence. Lack of blinding is a weakness in all 
of these studies. This becomes a challenge when the main 
outcome is subjective, pain, and we have downgraded for 
Figure 7 Ketamine and N2O versus only N2O—change in pain score.
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high risk of bias. However, there is moderate quality of 
the evidence for the main outcome, change in pain score, 
for one of the comparisons.
This systematic review has the benefit of systematic 
and transparent preplanned methodology. Decisions 
and judgements were conducted by two authors inde-
pendently of each other, hence, reducing the risk of bias 
in the conduct of the review. We conducted a wide litera-
ture search in several databases, but it is still possible that 
there exist relevant studies that we did not identify, both 
in other databases and in other languages. As always with 
systematic reviews, there is the possibility that relevant 
studies may have been published after our search was 
conducted. Our deviation from the protocol to include 
a large study even though it included some children may 
be interpreted as a limitation. However, we would argue 
that the inclusion of extra patients (1876 patients added 
to the 884 patients from the other seven studies), where 
the large majority was adults adds greatly to the available 
information regarding side effects/adverse events.
Two of the studies were conducted in Iraq and in 
Vietnam, respectively, where a number of patients were 
injured in mine accidents. These studies were the largest 
studies and included 1909 patients. It is reasonable to 
assume that the results from studies conducted in war 
zones are not directly applicable in civilian settings since 
the victims tend to be men, relatively young and previ-
ously healthy and are not representative of trauma victims 
in general. The study from Iraq did not report on any of 
our predefined outcomes.
Clinical implications
Ketamine administered in analgesic doses (0.1–0.2 mg/
kg) intravenously appears to be at least as effective as 
opioids administered alone considering pain reduc-
tion. In the study from Iraq, an initial dose of ketamine 
(0.2 mg/kg) was given in all cases of penetrating trauma 
and burns, but patients with TBI or blunt injury received 
only pentazocine.19 The patients in the study conducted 
by Tran et al received 0.2–0.3 mg/kg intravenous of 
ketamine.26 Four22–25 of the other five studies included 
studies administered ketamine in 0.2–0.3 mg/kg intra-
venous doses, while in the last intravenous study,20 the 
patients received 10–20 mg intravenous. of ketamine. 
In the study where ketamine was administered intrana-
sally, the patients received an average of 0.75 mg/kg of 
ketamine.21 Hence, the patients in all studies received 
appropriate analgesic doses of ketamine.
Adverse events
In general, very few adverse events were reported in 
the included studies. Most of the events were related to 
nausea and vomiting. Agitation was more common in 
the ketamine group in the study performed by Tran et 
al.26 Bronsky et al reported that two patients experienced 
respiratory compromise and two suffered haemodynamic 
















































































































































































































































































































































































































































































































































































































































































































































































































 on January 13, 2021 at H








pen: first published as 10.1136/bm






12 Sandberg M, et al. BMJ Open 2020;10:e038134. doi:10.1136/bmjopen-2020-038134
Open access 
Given the safety profile of ketamine and the results 
reported in the included studies, it appears reasonable 
to suggest that low- dose ketamine for analgesic purposes 
can be administered safely during prehospital emergency 
care when proper indications and contraindications are 
identified. Prehospital healthcare providers with a level 
of training suitable to administer ketamine—that is, 
personnel that are trained to handle potential adverse 
events—must be identified. None of the included studies 
had enough power to detect differences in rare events, 
and the quality of evidence was poor. One of the studies 
showed an increased number (pooled) of adverse events 
in the group receiving ketamine and morphine, indi-
cating that an improved analgesic effect increases the risk 
for adverse events. It is unclear whether adverse events 
are more likely to occur with opioids than with ketamine. 
However, it is essential to note that this review describes 
ketamine administered in analgesic doses and not in 
sedative and anaesthetic doses where advanced skills are 
required to be able to handle the patient in an adequate 
manner.
Studies from other settings
In a recent systematic review and meta- analysis, Yousefi-
fard et al included seven studies and pooled the effect esti-
mates of observational and randomised interventional 
studies.29 They concluded that ketamine is an effective 
and safe medication in prehospital pain management 
in patients with trauma and can be considered as an 
acceptable alternative to opioids. The analgesic effect of 
low- dose ketamine is also employed in the hospital. In a 
recent systematic review and meta- analysis, Karlow et al 
studied ketamine as an alternative to opioids for acute 
pain in the emergency department (ED).30 The authors 
concluded that ketamine can be used as an alternative 
to opioids in the ED, as they found that ketamine was 
non- inferior to opioids. They also found that the rate 
of non- severe adverse effects was higher with ketamine. 
It is unclear to what extent results from ED studies can 
be extrapolated to the prehospital setting. However, it 
is not obvious that the safety profile of ketamine in the 
prehospital setting is independent of the qualifications 
of the healthcare provider that administers the drug. 
Studies specifically addressing competence of prehos-
pital providers administering ketamine should there-
fore be conducted. The body of evidence for benefit 
and possible harm is limited as few studies have been 
performed. Future studies need to address all relevant 
side effects, the optimal drug dose as well as all relevant 
outcome measures.
CONCLUSION
This systematic review of the current literature indicates 
that ketamine is an effective analgesic to be administered 
prehospitally.
Author affiliations
1Division of Prehospital Services, Air Ambulance Department, Oslo University 
Hospital, Oslo, Norway
2Faculty of Medicine, University of Oslo, Oslo, Norway
3Faculty of Health Sciences, University of Stavanger, Stavanger, Norway
4Department of Research, Norwegian Air Ambulance Foundation, Oslo, Norway
5Trauma Unit, Sørlandet Hospital, Kristiansand, Norway
6Department of Prehospital Care and Disaster Medicine, Region of Skåne, Lund, 
Sweden
7Research Department, Prehospital Emergency Medical Service, Central Denmark 
Region, Aarhus, Denmark
8Department of Anaesthesiology, Regional Hospital of Horsens, Horsens, Denmark
9Centre for Prehospital Emergency Care, Oulu University Hospital, Oulu, Finland
10Anaesthesia Research group, MRC, Oulu University Hospital and University of 
Oulu, Oulu, Finland
11Department of Anaesthesiology and Intensive Care, Linköping University Hospital, 
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